News | July 12, 2025
Briefs: Emcure Pharmaceuticals and Gland Pharma
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
It is intended for contrast enhancement in MRI scans
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Alkem Medtech to acquire 100% stake of Bombay Ortho
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
USFDA inspection at Emcure Pharmaceuticals API facility
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Subscribe To Our Newsletter & Stay Updated
